In a patient recovering from dengue fever who now has elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), what is the appropriate management?

Management of Post-Dengue Elevated Transaminases

In a patient recovering from dengue with elevated AST and ALT, provide supportive care with close monitoring and serial liver function tests every 2-3 days, as hepatic involvement is self-limiting in >95% of cases with normalization occurring within 2 weeks. 1, 2

Initial Assessment and Risk Stratification

The severity of transaminase elevation determines your management approach 3, 4:

• Mild elevation (<5× upper limit normal): Outpatient monitoring acceptable
• Moderate (5-10× ULN) or Severe (>10× ULN): Requires hospitalization and closer surveillance
• AST typically exceeds ALT in dengue hepatitis—this is the characteristic pattern 5, 1

Key Clinical Parameters to Monitor

Check for signs requiring expeditious evaluation 3:

• Coagulopathy (prolonged PT/INR >1.5)
• Hyperbilirubinemia (especially conjugated)
• Hypoalbuminemia
• Encephalopathy or altered mental status
• Evidence of hepatic decompensation

Critical caveat: Hypertension increases risk of hepatic cytolysis 2.3-fold in dengue patients 2—these patients warrant closer monitoring.

Management Algorithm

For Mild-Moderate Elevation (Most Common Scenario)

Supportive care remains the cornerstone 5, 1:

• Serial monitoring: Repeat AST/ALT every 2-3 days until downtrending
• Hydration: Maintain adequate fluid balance
• Avoid hepatotoxins: Stop all non-essential medications, alcohol, herbal supplements
• Platelet monitoring: 12.2% with hepatic dysfunction require transfusion vs 1.3% without 1
• Expected timeline: Transaminases normalize in 95.5% of cases with mean recovery of 13 days 2

For Severe Elevation or Deterioration

If transaminases remain markedly elevated >6 months or clinical deterioration occurs 3:

1. Exclude alternative diagnoses with serologic testing:

   • Hepatitis A, B, C serology (especially if on medications like antitubercular therapy) 6
   • Autoimmune markers if clinically indicated
   • Drug-induced liver injury assessment

2. Consider imaging: Ultrasound to exclude biliary obstruction or structural abnormalities 4

3. Assess for acute liver failure: If INR >1.5, encephalopathy, or rapidly rising bilirubin, consider therapeutic plasma exchange 7

Adjuvant Therapy Consideration

N-acetylcysteine (NAC) has been reported in severe dengue hepatitis 5, 8:

• Oral NAC was used as adjuvant therapy in cases with AST >2000 U/L
• Important limitation: No controlled trials exist; temporal improvement may reflect natural disease course 8
• Consider in severe cases (AST >10× ULN) as low-risk adjunct, but recognize evidence is anecdotal

Common Pitfalls to Avoid

1. Don't assume all transaminitis is dengue-related: Rule out concurrent viral hepatitis, especially in patients on hepatotoxic medications 6

2. Don't discharge too early: Patients with hepatic dysfunction have significantly longer hospital stays (median 5 vs 3 days) 1—premature discharge risks missing deterioration

3. Don't overlook the AST:ALT ratio: If ALT >> AST or isolated ALT elevation, consider non-dengue etiologies 4, 5

4. Don't order unnecessary tests initially: If clinical picture fits post-dengue hepatitis with mild-moderate elevation and no red flags, observation with serial monitoring is appropriate 3

Expected Clinical Course

The prognosis is excellent in the vast majority 1, 2:

• Peak transaminases typically occur day 4-5 of illness
• Normalization within 2 weeks in >95% of cases
• Case fatality rate 7% in severe dengue with hepatic involvement 2
• Mortality primarily in those developing acute liver failure (rare) 7

Monitor closely but avoid overinvestigation in straightforward cases—the natural history favors complete recovery with supportive care alone.